Innocan Pharma Announces Closing of $5.1 Million Prospectus Offering of Units
Toronto, Ontario--(Newsfile Corp. - June 10, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce the closing of its marketed short form prospectus offering pursuant to which the Company issued 28,423,943 units of the Company (the "Units") at a price of $0.18 per Unit for gross proceeds of $5,116,309.74 (the "Offering"). The Offering was led by Mackie Research Capital Corporation, as sole bookrunner, and Canaccord Genuity Corp. as...
2020-06-10 10:00 AM EDT
InnoCan Pharma Announced the Commencement of its Derma CBD Line Commercial Production in Portugal
Alberta and Tel Aviv, Israel--(Newsfile Corp. - June 5, 2020) - InnoCan Pharma (CSE: INNO) ("InnoCan" or the "Company") is pleased to announce the commencement of commercial production if Derma CBD line in Portugal. The first product which are currently manufactured is The Patent Pending Relief & Go CBD Spray, one of InnoCan's flagship products, developed by chief technology officer Nir Avram.Nir Avram the company's CTO T commented: "The patent pending unique formulation of Relief & Go...
2020-06-05 2:57 AM EDT
Innocan Pharma Amends Terms of Marketed Short Form Prospectus Offering of Units
Toronto, Ontario--(Newsfile Corp. - June 2, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), announces that it has amended certain terms of its marketed offering of units of the Company (the "Units"), that was previously announced on May 11, 2020 and May 14, 2020 (the "Offering"). Pursuant to the amended terms, the Offering of Units will be conducted at a price of $0.18 per Unit for minimum gross proceeds of $2,500,000 and maximum gross proceeds...
2020-06-02 7:24 AM EDT
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Psoriasis Treatment
Alberta and Tel Aviv, Israel--(Newsfile Corp. - May 28, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its wholly-owned subsidiary, Innocan Pharma Ltd. ("Innocan Israel"), filed an international patent application for a novel cannabis-based psoriasis treatment. This patent application makes claim of a topical pharmaceutical composition used to treat the symptoms of itching and inflammation associated with psoriasis."The...
2020-05-28 2:52 AM EDT
InnoCan Pharma Enters into Letter of Intent to Develop and Produce Exosomes for Use in its CBD-Loaded Exosome (CLX) Treatments
Alberta and Tel Aviv, Israel--(Newsfile Corp. - May 22, 2020) - InnoCan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its wholly-owned subsidiary, Innocan Pharma Ltd. ("Innocan Israel"), has entered into a letter of intent ("LOI") with Adva Biotechnology Ltd. ("ADVA") dated May 21, 2020. The LOI sets out the indicative terms of an exosome production and development agreement (the "Exosome Production Agreement") which the parties intend to...
2020-05-22 3:00 AM EDT
Innocan Pharma Announces Pricing of Marketed Short Form Prospectus Offering of Units
Toronto, Ontario--(Newsfile Corp. - May 14, 2020) - Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that it has priced its previously announced marketed offering of units of the Company (the "Units") at a price of $0.20 per Unit (the "Offering Price") to raise aggregate gross proceeds of up to $10,000,000 (the "Offering"). Each Unit shall be comprised of one common share of the Company (a "Common Share") and one Common Share purchase...
2020-05-14 7:25 AM EDT
RETRANSMISSION: Innocan Pharma Announces up to $10 Million Public Offering of Units
Toronto, Ontario--(Newsfile Corp. - May 12, 2020) - (reissued May 12, 2020) Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that it has filed and been receipted for a preliminary short form prospectus with the securities regulatory authorities in all provinces of Canada (except Québec) in connection with a marketed public offering (the "Offering") of units of the Company ("Units") for gross proceeds of up to $10,000,000. The Offering is...
2020-05-12 7:48 AM EDT
Innocan Pharma Announces up to $10 Million Public Offering of Units
Toronto, Ontario--(Newsfile Corp. - May 11, 2020) - Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan") is pleased to announce that it has filed and been receipted for a preliminary short form prospectus with the securities regulatory authorities in all provinces of Canada (except Québec) in connection with a marketed public offering (the "Offering") of units of the Company ("Units") for gross proceeds of up to $10,000,000. The Offering is being led by Mackie...
2020-05-11 5:21 PM EDT
InnoCan Announces Appointment of Professor Daniel Offen, Scientific Advisory Director
Israel and Calgary, Alberta--(Newsfile Corp. - May 1, 2020) - InnoCan Pharma Corporation (CSE: INNO) ("InnoCan" or the "Company") announced that its wholly-owned subsidiary, InnoCan Pharma Ltd. of Herzliya Israel, has announced today that the Management of InnoCan has appointed Prof. Daniel Offen, of the Sackler School of Medicine, Sagol School of Neuroscience at Tel Aviv University, to its Scientific Advisory Committee.Recently, on April 17th InnoCan announced that its wholly-owned...
2020-05-01 4:00 PM EDT
InnoCan to Develop a New Lines of CBD Products for Tamar Technologies
Israel and Calgary, Alberta--(Newsfile Corp. - April 28, 2020) - InnoCan Pharma Corporation (CSE: INNO) (FSE: IP4) ("InnoCan" or the "Company") announced that its major shareholder Tamar Technologies Ltd (formerly Solsken Ltd) ("Tamar"), has notified InnoCan of its intention to exercise its rights to license InnoCan's formulations and know-how for existing CBD products and new CBD formulations pursuant to the Cooperation Agreement between Tamar and InnoCan's wholly-owned subsidiary, InnoCan...
2020-04-28 4:00 PM EDT
InnoCan Pharma Collaborates with Tel Aviv University to Develop a New Revolutionary Approach to Treat the COVID-19 Corona Virus with Exosomes-Loaded CBD
Israel and Calgary, Alberta--(Newsfile Corp. - April 17, 2020) - InnoCan Pharma Corporation (CSE: INNO) ("InnoCan" or the "Company") announced that its wholly-owned subsidiary, InnoCan Pharma Ltd. of Herzliya Israel, has entered into a sponsored research agreement dated April 17, 2020 (the "Research Agreement") with Ramot at Tel Aviv University ("Ramot") to collaborate with Tel Aviv university to develop a novel, revolutionary approach to treat COVID-19 by using Cannabidiol (CBD) loaded...
2020-04-17 4:46 PM EDT
InnoCan Provides Update and Summary About Its Corporate Progress as Its First Products Prepare to Enter the Commercial Marketplace
Calgary, Alberta--(Newsfile Corp. - February 11, 2020) - InnoCan Pharma Corporation (CSE: INNO) ("InnoCan" or the "Company"), today provided an update and summary of its activities and achievements as a public company during its first five months. All supporting documents and references can be found at www.sedar.comIris Bincovich, InnoCan's CEO, said, "InnoCan has made significant strides in less than two quarters as a public company. We are successfully executing our business plan and, in...
2020-02-11 10:35 AM EST
InnoCan Pharma Announces Patent Application for Novel Hemorrhoid Treatment
Israel and Calgary, Alberta--(Newsfile Corp. - February 5, 2020) - InnoCan Pharma Corporation (CSE: INNO) ("InnoCan" or the "Company") announced today the filing of a new patent application for a cannabis-based formula targeting the pain, swelling and inflammation associated with hemorrhoids.Hemorrhoids are the fourth leading gastrointestinal disease diagnosed in outpatient settings. This accounts for approximately 3.3 million ambulatory care visits. Furthermore 10 million cases per year are...
2020-02-05 9:00 AM EST